Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Priyanka Iyer et al.|Thyroid|2024Cited by 72
Toxicity in the era of immune checkpoint inhibitor therapySynat Keam, Roza Nurieva, Naimah Turner et al.|Frontiers in Immunology|2024Cited by 56
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistanceSarah Hamidi, Ramona Dadu, Marie‐Claude Hofmann et al.|Frontiers in Endocrinology|2023Cited by 49
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|JAMA Oncology|2024Cited by 35
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side EffectsSarah Hamidi, Hortensia Mircescu, Andrée Boucher et al.|Journal of the Endocrine Society|2022Cited by 22